GLP-1 therapies have transformed metabolic and obesity treatment, but limitations such as limited durability, gastrointestinal side effects, variable patient response, and gaps in addressing broader metabolic pathways highlight the need for fresh approaches. This workshop shines a spotlight on the next wave of GPCR targets poised to expand treatment options and precision care. From tackling tough class B receptors to pioneering novel therapeutic modalities, we’ll explore the cutting-edge strategies reshaping how we approach metabolic diseases and obesity. Join us to discover the future beyond GLP-1, bridging the gap between innovation and unmet patient needs.

Key Takeaways:

• Discuss the limitations of GLP-1 therapies in precision medicine and expand therapeutic reach beyond GLP-1 by exploring emerging GPCR targets like amylin, GRP, and orphan receptors to better serve underserved patient subgroups
• Share approaches to identify ligands for challenging class B GPCRs with large or poorly defined binding pockets, using orthosteric/allosteric strategies, PAM/NAM sensitisation, and advanced virtual or high-throughput screening tools
• Advance next-gen GPCR therapeutics through peptide, antibody, or bispecific engineering, optimising half-life, pharmacokinetics, and combination strategies with mechanisms like immune checkpoint modulation